National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Anencephaly is not the name you expected.

Disorder Subdivisions

  • None

General Discussion


Anencephaly is a term that refers to the incomplete development of the brain, skull, and scalp and is part of a group of birth defects called neural tube defects (NTD). The structure which will become the neural tube is supposed to fold and to close together (to form a tube) during the third and fourth weeks of pregnancy. From this neural tube, the brain and spinal cord of the embryo develop. Neural tube defects happen when the neural tube does not close as expected. Anencephaly occurs when the end of the neural tube that would have developed into the brain does not close properly, resulting in the failure of the development of major portions of brain, skull and scalp. Other neural tube defects, such as spina bifida, form when the neural tube does not close properly in a different part of the neural tube.

Infants with anencephaly are born without the front part of the brain, (forebrain) and the thinking and coordinating part of the brain (cerebral hemispheres and cerebellum). Most of the time the remaining brain tissue may be exposed, without skull or scalp to cover and protect it. Although reflex actions such as breathing and responses to touch or sound may occur, gaining consciousness is not possible. Usually infants with anencephaly do not survive more than a few days or weeks.


Meroanencephaly and holoanencephaly are terms refer to the extent of the cranial defect, however, they typically are not used in clinical descriptions and are not predictive of severity of the condition. The term acrania has been used interchangeably with anencephaly in some parts of the world but that practice is discouraged as it confuses two very different conditions.


Pregnancies affected by anencephaly show high levels of a specific fetal protein (called alpha fetoprotein) in tests done on the mother's blood or on amniotic fluid. The presence of excess fluid in the amniotic sac that contains the fetus (polyhydramnios) may be noted during an ultrasound.

Anencephaly may also be seen before birth using any one of several imaging techniques. The condition is characterized by the absence of the skull and parts of the brain (cerebral hemispheres and cerebellum). Abnormalities of facial features secondary to the absent skull are common and vary depending on the development of each fetus. Anencephaly usually (~80%) occurs without other birth defects.


Not all of the causes of anencephaly are understood. Anencephaly can be a multifactorial condition meaning that multiple genes are involved interacting with environmental agents and chance events to cause the condition. Anencephaly can also be a feature of some chromosomal disorders such as trisomy 18 which are usually sporadic and not familial (inherited).

Most times anencephaly occurs in a pregnancy where there is no family history of neutral tube defects. However, research has shown that once a woman has had one pregnancy that resulted in a fetus with a neural tube defect, any additional pregnancies have an increased risk that a similar defect will occur again (recurrence risk). This recurrence risk is estimated to be 3-4% compared to the background risk of much less than 1%. Researchers also expect that if a subsequent fetus has a neural tube defect, the defect, whether anencephaly or spina bifida, tends to be in a location similar to the prior pregnancy.

While not all the causes of anencephaly are known, many epidemiologic studies have demonstrated that folic acid supplementation prior to conception and during the first trimester can reduce the birth prevalence of spina bifida and anencephaly by at least 50%.

Affected Populations

Many fetuses with anencephaly are stillborn or are spontaneously aborted, but more females are born with anencephaly than males.

Beginning in January 1998, the US Food and Drug Administration mandated that folic acid be added to all enriched cereal grain products. After this mandate, anencephaly affects about 1 in per 5,000 to 10,000 births in the U.S. Internationally, the number of births affected varies and is greatly influenced by the use of folic acid supplementation or food fortification, prenatal diagnosis, and pregnancy termination.

Standard Therapies


The U.S. Public Health Service advises women of childbearing age to take 0.4 mg of folic acid daily, either through supplements or fortified foods, even if those women do not think they are likely to become pregnant. This is recommended because the neural tube forms early, often before women realize they are pregnant.

Women are urged not to take more than 1.0 mg of folic acid daily unless advised by a physician because high doses of folic acid may mask the diagnosis of severe B12 deficiency (pernicious anemia).

Women who have had a previous pregnancy affected by a neural tube defect are advised to consume 4 mg of folic acid beginning 30 days before conception through the first trimester under the care of their physician.


Infants with anencephaly usually do not survive more than a few days or weeks. The role of healthcare providers is to provide a supportive environment that will enable the family to accept the diagnosis and make preparations for their loss.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:



Holmes LB. Common Malformations. New York, NY: Oxford University Press; 2012:218-35.

Jones KL, ed. Smith's Recognizable Patterns of Human Malformation. 6th ed. Philadelphia, PA: WB Saunders Company; 2006:704-05.

Hunter AG. Brain and Spinal Cord. In: Stevenson RE, ed.. Human Malformations and Related Anomalies. 2nd ed. New York, NY: Oxford University Press; 2006:715-55.

Wyszynski DF, ed. Neural Tube Defects From Origin to Treatment. New York, NY: Oxford University Press; 2006


Greenberg JA, Bell SJ, Guan Y. et al. Folic Acid supplementation and pregnancy: more than just neural tube defect prevention. Rev Obstet Gynecol. 2011;4(2):52-9.

Harris MJ, Juriloff DM. An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. Birth Defects Res A Clin Mol Teratol. 2010;88:653-69.

Copp AJ, Greene ND. Genetics and development of neural tube defects. J Pathol. 2010;220(2):217-30.

Parker SE, Mai CT, Canfield MA, Rickard R, et al; National Birth Defects Prevention Network. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol. 2010;88(12):1008-16.

Boulet SL, Yang Q, Mai C, et al. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol. 2008;82:527-32.

Boyd PA, Devigan C, Khoshnood B, et al. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. BJOG. 2008;115:689-96.

Kooper AJ, de Bruijn D, van Ravenwaaij-Arts CM, et al. Fetal anomaly scan potentially will replace routine AFAFP assays for the detection of neural tube defects. Prenat Diagn. 2007;27:29-33.

Farley TL. A reproductive history of mothers with spina bifida offspring--a new look at old issues. Cerebrospinal Fluid Res. 2006:3:10.

Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD. Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995-2002. Pediatrics. 2005;116(3):580-6.

Norem CT, Schoen EJ, Walton DL, et al. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening. Obstet Gynecol. 2005;106:747-52.

Centers for Disease Control and Prevention (CDC). Spina bifida and anencephaly before and after folic acid mandate--United States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep. 2004;53(17):362-5.

Green NS. Folic acid supplementation and prevention of birth defects. J Nutr. 2002;132(8 suppl):2356S-2360S.

O'Rahilly R, Muller F. The two sites of fusion of the neural folds and the two neuropores in the human embryo. Teratology. 2002;65:162-70.

Honein MA, Paulozzi LJ, Mathews TJ, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA. 2001;285:2981-86

Drugan A, Weissman A, Evans MI. Screening for neural tube defects. Clin Perinatol. 2001;28:279-87.

Sen C. The use of first trimester ultrasound in routine practice. J Perinat Med. 2001;29:212-21.

Cragan JD, Roberts HE, Edmonds LD, et al. Surveillance for anencephaly and spina bifida and prenatal diagnosis. United States, 1985-1994. MMWR Morb Mortal Wkly Rep. 1995;44(SS-4):1-13.


Folic Acid. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. // Last Updated March 10, 2011. Accessed August 1, 2012.

Supporting Organizations

Birth Defect Research for Children, Inc.

976 Lake Baldwin Lane
Orlando, FL 32814
Tel: (407)895-0802
Website: //

Fetal Hope Foundation

9786 South Holland Street
Littleton, CO 80127
Tel: (303)932-0553
Tel: (877)789-4673
Website: //

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126
Gaithersburg, MD 20898-8126
Tel: (301)251-4925
Fax: (301)251-4911
Tel: (888)205-2311
Website: //

Infants Remembered In Silence, Inc. (IRIS)

112 Third Street NE
Faribault, MN 55021
Tel: (507)334-4748
Fax: (507)334-4748
Website: //

NIH/National Institute of Child Health and Human Development

31 Center Dr
Building 31, Room 2A32
Bethesda, MD 20892
Fax: (866)760-5947
Tel: (800)370-2943
Website: //

NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801
Bethesda, MD 20824
Tel: (301)496-5751
Fax: (301)402-2186
Tel: (800)352-9424
Website: //

Share Pregnancy & Infant Loss Support, Inc.

402 Jackson Street
Saint Charles, MO 63301
Tel: (636)947-6164
Fax: (636)947-7486
Tel: (800)821-6819
Website: //

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see